跳至主要内容
临床试验/NCT03861351
NCT03861351已完成不适用

A Multicenter, Non-controlled and Open-label Trial Following Subjects Implanted Bilaterally With the Toric Extended-depth-of-focus Mini WELL Toric Ready Intraocular Lens for 6 Months After the Second Eye Implant

SIFI SpA8 个研究点 分布在 3 个国家目标入组 58 人开始时间: 2019年9月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
SIFI SpA
入组人数
58
试验地点
8
主要终点
Rate of severe visual distortions

研究概览

简要总结

This is a multicenter, non-comparative trial following participants implanted bilaterally with the Mini WELL Toric Ready intraocular lens (IOL) for 6 months after the second eye implant.

The objective of the study is to evaluate the clinical performance of the Mini WELL Toric Ready intraocular lens (IOL), in particular, visual performance and rotational stability at 6 months following the second eye implantation in participants suffering from bilateral cataract with corneal astigmatism.

There are 2 hypotheses:

  • Rotational Stability: the rotation of the Mini WELL Toric Ready IOL compared between Visit 0a (the day of surgery) and Visit 4 (120 180 days post-operative follow-up) shall be less than ±10° in 90% of the cases.
  • Severe Visual Distortions: the rate of severe visual distortions for the Mini WELL Toric Ready IOL reported at 6 months postoperative will be less than 10 percents.

详细描述

This is an interventional, multicenter, non-comparative post-marketing clinical investigation in participants implanted bilaterally with the Mini WELL Toric Ready intraocular lens (IOL) for 6 months after the second eye implant.

The objective of this study is to evaluate the clinical performance of the Mini WELL Toric Ready IOL, in particular, visual performance and rotational stability at 6 months following second eye implantation.

The first hypothesis raised for this study is related to rotational stability. The rotation of the Mini WELL Toric Ready IOL compared between Visit 0a (the day of surgery) and Visit 4 (120 180 days post-operative follow-up) shall be less than ±10° in 90% of the cases.

The second hypothesis is regarding severe visual distortions. The rate of severe visual distortions for the Mini WELL Toric Ready IOL reported 6 months post-operative will be less than 10 percents.

The study will involve 45participants in 3 countries in order to achieve a target number of 38 evaluable participants completing the study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Eighteen years of age or older at the time of surgery and diagnosed with bilateral cataracts;
  • Planned bilateral cataract removal by phacoemulsification;
  • Preoperative total corneal astigmatism of 0.89 - 2.91 D, measured by corneal topography in both operative eyes;
  • IOL power and cylinder requirement calculated by the specific web-based Mini Toric Calculator within the following range:
  • Cylinder of: 1.50 D to 4.00 D
  • Spherical Equivalent of: 18.00 to 28.00 D
  • Willing and able to complete all required postoperative visits;
  • Clear intraocular media other than cataract;
  • Available for second-eye surgery within 2 weeks of the initial operation;
  • Potential postoperative visual acuity of 0.3 logMAR in both eyes;
  • Able to comprehend and sign a statement of informed consent consistent with local regulation for research in human subjects.

排除标准

  • Irregular / asymmetric astigmatism;
  • Significant irregular corneal aberration as demonstrated by corneal topography;
  • Keratopathy / Kerectasia - any corneal abnormality, other than regular corneal astigmatism, including, but not limited to the following: keratoconus, keratoglobus, keratolysis, keratomalacia, keratomicosis and corneal plana;
  • Any inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjuntivitis and keratouveitis;
  • Subjects with diagnosed degenerative visual disorder (e.g. macular degeneration or other retinal disorders) that are predicted (by subjective assessment of the retina) to cause future acuity losses to a level worse than 0.3 logMAR;
  • Subjects who may have reasonably been expected to require a secondary surgical intervention at any time during the study (other than Nd:YAG capsulotomy);
  • Subjects in whom the intraocular lens might interfere with the ability to observe, diagnose or treat posterior segment conditions;
  • Previous corneal refractive surgery;
  • Other planned ocular surgery procedures, including, but not limited to LASIK, astigmatic keratotomy, retinal laser treatment and limbal relaxing incisions, for the duration of the study;
  • Capsular or zonular abnormalities that may affect postoperative centration or tilt of the lens, including but not limited to the following: pseudo-exfoliation syndrome, chronic uveitis, Marfan's Syndrome;
  • Absence of adequate capsular support for the implant of the intraocular lens in the capsular bag;
  • Absence of adequate support for the lens from the posterior chamber or the zonule;
  • Pupil abnormalities, including but not limited to the following: non-reactive, tonic pupils that do not dilatate under mesopic/scotopic conditions, abnormally shaped pupils or abnormally positioned pupils;
  • Amblyopia;
  • Clinically severe corneal dystrophy (e.g. epithelial, stromal, or endothelial dystrophy);
  • Proliferative diabetic retinopathy;
  • Microphthalmos;
  • Suspected microbial infection;
  • Previous retinal detachment;
  • Previous corneal transplant;
  • Optic nerve atrophy;
  • Extremely shallow anterior chamber, not due to swollen cataract;
  • Recurrent severe anterior or posterior segment inflammation of unknown aetiology (e.g. chronic uveitis);
  • Iris neovascularization;
  • Glaucoma (uncontrolled or controlled with medication);
  • Aniridia or iris atrophy;
  • Severe dry eye;
  • Use of any systemic or topical drug known to interfere with visual performance;
  • Subjects with any systemic disease that could increase operative risk or confound the outcomes (e.g. uncontrolled diabetes);
  • Use of contact lens within the last 30 days before the preoperative visit;
  • Vulnerable subjects (children <18 years, people in guardianship or trusteeship or inability to give an informed consent);
  • Pregnant or lactating or planning a pregnancy at the time of enrolment;
  • Subjects with psychiatric disorders that could confound the outcomes;
  • Subjects participating in a concurrent clinical trial or if they have participated in an ophthalmology clinical trial within the last 30 days.
  • Intra-operative exclusion criteria:
  • Irregularity and decentration of capsulorhexis;
  • Other ocular surgery procedures, including, but not limited to LASIK, astigmatic keratotomy, retinal laser treatment and limbal relaxing incisions, for the duration of the study;
  • Significant vitreous loss;
  • Significant anterior chamber hyphema;
  • Uncontrollable intraocular pressure (IOP);
  • Zonular or capsular rupture;
  • Ciliary sulcus, Bag-sulcus, sulcus-sulcus or unknown placement of the haptics.

结局指标

主要结局

Rate of severe visual distortions

时间窗: 6 months after second eye implant

To evaluate the visual performance of Mini WELL Toric Ready IOL.

Intraocular lens (IOL) rotation

时间窗: 6 months after second eye implant

To evaluate the rotational stability of Mini WELL Toric Ready IOL.

次要结局

未报告次要终点

研究者

发起方
SIFI SpA
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验